Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly EBT Margin of 35.61% for Q2 2026, down 571.0% year-over-year from 7.56% in Q2 2025, and up 54.45% quarter-over-quarter from 23.05% in Q1 2026.
Regeneron Pharmaceuticals (REGN) EBT Margin (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' EBT Margin history runs 18 years deep, the most recent figure standing at 35.61% for Q2 2026.
- In Q2 2026, EBT Margin fell 571.0% year-over-year to 35.61%; the TTM figure through Jun 2026 stood at 33.25% (down 104.0% YoY), while the FY2025 annual figure was 36.47%, up 281.0% from the prior year.
- EBT Margin for Q2 2026 stood at 35.61%, up from 23.05% in the prior quarter.
- The five-year high for EBT Margin was 2122.2% in Q1 2022, with the low at 22.28% in Q1 2024.
- The 5-year median for EBT Margin is 34.0% (2022), against an average of 222.07%.
- The sharpest annual moves came in 2022 and 2023: EBT Margin surged 207265 bps in 2022, then sank 209507 bps in 2023.
- Regeneron Pharmaceuticals' EBT Margin stood at 1324.7% in 2022, then sank by 97 bps to 33.42% in 2023, then slipped by 24 bps to 25.29% in 2024, then increased by 6 bps to 26.87% in 2025, then jumped by 33 bps to 35.61% in 2026.
- Business Quant data shows REGN's EBT Margin at 35.61% in Q2 2026, 23.05% in Q1 2026, and 26.87% in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 41.75% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 35.61% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 34.77% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 18.33% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -94.22% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 13.77% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -2.67% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -20,427.46% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 35.61% |
| Mar 31, 2026 | 23.05% |
| Dec 31, 2025 | 26.87% |
| Sep 30, 2025 | 46.97% |
| Jun 30, 2025 | 41.32% |
| Mar 31, 2025 | 29.88% |
| Dec 31, 2024 | 25.29% |
| Sep 30, 2024 | 40.13% |
| Jun 30, 2024 | 45.90% |
| Mar 31, 2024 | 22.28% |
| Dec 31, 2023 | 33.42% |
| Sep 30, 2023 | 33.03% |
| Jun 30, 2023 | 34.29% |
| Mar 31, 2023 | 27.13% |
| Dec 31, 2022 | 1,324.70% |
| Sep 30, 2022 | 51.42% |
| Jun 30, 2022 | 33.71% |
| Mar 31, 2022 | 2,122.20% |
| Dec 31, 2021 | 50.56% |
| Sep 30, 2021 | 52.61% |